Lyell Immunopharma, Inc. Research And Development Expense

Quick Answer

Lyell Immunopharma, Inc. reported Research And Development Expense of $182.95 million for the year ending 2023.

  • Lyell Immunopharma, Inc. showed an increase of +14.9% in Research And Development Expense from 2022 to 2023.
  • This data is from Lyell Immunopharma, Inc.'s annual report (Form 10-K), filed with the SEC on February 28, 2024.
  • XBRL data for this metric is available from 2019 to 2023 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 5 years of available data (2019 to 2023), Lyell Immunopharma, Inc.'s Research And Development Expense has grown by 187.7%.
  • Historical annual values: Fiscal year 2023: $182.95 million | Fiscal year 2022: $159.19 million | Fiscal year 2021: $138.69 million | Fiscal year 2020: $182.24 million | Fiscal year 2019: $63.60 million.
  • Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: